Item 8.01. Other Events.
On May 6, 2021, the Company issued a press release announcing twelve and
twenty-four month data from certain dosing groups in its ongoing X-linked
retinitis pigmentosa (XLRP) phase 1/2 clinical trial. A copy of this press
release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release dated May 6, 2021.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses